The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Maybe a little sell off after the DLG update?
Anyway, glad to say I took advantage at 2442p.
Well, I bought in yesterday on the premise that “investors” these days are jittery and feel the need to constantly tweak their p/f’s based on over reaction.
The slight negatives are amplified whilst the positive notes are ignored.
Group revenue up 9%
Core operating profit up 12%
Cash flow up 38%
Net debt x 0.6 EBITD
Core operating margin 35-37%
The share price is in a down ward trend but this is a fantastic recovery play for when Mr Market realises value.
Strong brand names, quality products and good margins are all playing their part in a good trading update and are helping the company navigate the choppy waters out there.
Hopefully the momentum from the last update is carried through in these difficult times.
Close to £1.4M worth of shares bought by company insiders and associates. Looks like like they took advantage of the over selling as well.
An investment case put forward by Hargreaves Lansdown.
https://www.hl.co.uk/features/five-shares-for-2022
Bullish by RTO to issue an RNS with the line “S&P Global ratings is expected to move the Business Risk Profile from Satisfactory to Strong to reflect the Group’s increased scale and no.1 position in the USA.”
Opened my position here at the end of Nov at 669p and will look to add on any irrational market sell off.
This has a similar feel to GSK as regards the market uncertainty on the company split.
Following on from the chairman, Philip Yea purchasing 5000 shares in October, a person closely associated to the CFO has bought heavily today by purchasing over 5000 shares.
Another sign of confidence.
Took the plunge and bought a few today.
All the Christmas adverts have been filmed with the air time bought.
Companies aren’t going to pull their adverts in this Golden Quarter and I
expect the next trading update to be extremely good.
The share price may well drift a little until the next trading update is issued but if it hits sub 180p I won’t think twice about topping up.
And yes, a 3% dividend paying defensive stock sits nicely in the stable.
For me, given the problems PZC have experienced in Nigeria I am glad the strategic review highlighted simplify the Nigerian arm of the business.